Who owns KALARIS THERAPEUTICS INC COM?
- Ticker: KLRS
- CUSIP Number: 482929106
Tip: Access positions for across all investors
Analyze quarterly positions in Kalaris Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Kalaris Therapeutics stock
Who bought or sold KALARIS THERAPEUTICS INC COM this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Samsara BioCapital | 13M | $75M | 0% | Mar 2026 |
|
| Rtw Investments | 1.3M | $11M | 100% | Dec 2025 |
|
| Paradigm Biocapital Advisors | 700k | $4.0M | 0% | Mar 2026 |
|
| Alyeska Investment Group | 573k | $3.3M | 42% | Mar 2026 |
|
| Siren | 436k | $3.7M | 37% | Dec 2025 |
|
| Ikarian Capital | 360k | $2.1M | 0% | Mar 2026 |
|
| Propel Bio Management | 296k | $1.7M | 603% | Mar 2026 |
|
| Vanguard Group | 293k | $2.5M | 44% | Dec 2025 |
|
| Vanguard Capital Management | 255k | $1.5M | 100% | Mar 2026 |
|
| Kalehua Capital Management | 136k | $782k | 100% | Mar 2026 |
|
| Goldman Sachs Group | 111k | $638k | 222% | Mar 2026 |
|
| Woodline Partners | 100k | $577k | 0% | Mar 2026 |
|
| ADAR1 Capital Management | 100k | $577k | 0% | Mar 2026 |
|
| Whi Trust | 98k | $563k | 100% | Mar 2026 |
|
| Boothbay Fund Management | 92k | $532k | 0% | Mar 2026 |
|
| Raymond James Financial | 88k | $746k | 100% | Dec 2025 |
|
| Renaissance Technologies | 88k | $741k | -22% | Dec 2025 |
|
| Geode Capital Management | 88k | $505k | 6% | Mar 2026 |
|
| Simplify Asset Management | 87k | $504k | 336% | Mar 2026 |
|
| Marshall Wace | 73k | $615k | 416% | Dec 2025 |
|
| Millennium Management | 60k | $344k | 100% | Mar 2026 |
|
| 683 Capital Management | 45k | $260k | -44% | Mar 2026 |
|
| Belpointe Asset Management | 40k | $231k | 0% | Mar 2026 |
|
| Fortis Capital Advisors | 40k | $231k | 0% | Mar 2026 |
|
| Squarepoint Ops | 40k | $230k | 57% | Mar 2026 |
|
| Morgan Stanley | 38k | $230k | 37% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 37k | $212k | 100% | Mar 2026 |
|
| BlackRock | 36k | $208k | -6% | Mar 2026 |
|
| Two Sigma Investments | 31k | $177k | 10% | Mar 2026 |
|
| State Street Corporation | 25k | $215k | 12% | Dec 2025 |
|
| Bridgeway Capital Management | 23k | $190k | 0% | Dec 2025 |
|
| Rbf Capital | 17k | $100k | 0% | Mar 2026 |
|
| Independent Advisor Alliance | 14k | $82k | 100% | Mar 2026 |
|
| Connor, Clark & Lunn Investment Management | 14k | $79k | 34% | Mar 2026 |
|
| Northern Trust | 14k | $115k | 100% | Dec 2025 |
|
| Susquehanna International | 13k | $109k | 100% | Dec 2025 |
|
| WealthTrust Asset Management | 12k | $72k | 100% | Mar 2026 |
|
| Hrt Financial | 12k | $67k | 100% | Mar 2026 |
|
| XTX Topco | 11k | $92k | 100% | Dec 2025 |
|
| Johnson Financial Group | 10k | $58k | 0% | Mar 2026 |
|
| Citigroup | 8.7k | $50k | 100% | Mar 2026 |
|
| FMR | 7.8k | $66k | 0% | Dec 2025 |
|
| UBS Group | 6.2k | $36k | 130% | Mar 2026 |
|
| Barclays | 6.1k | $51k | 100% | Dec 2025 |
|
| Nano Cap New Millennium Growth Fund | 4.0k | $34k | 100% | Dec 2025 |
|
| Steward Partners Investment Advisory | 2.2k | $13k | 100% | Mar 2026 |
|
| Vanguard Global Advisers | 725.00 | $4.2k | 100% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 652.00 | $3.8k | 1154% | Mar 2026 |
|
| Strengthening Families & Communities | 268.00 | $1.5k | 100% | Mar 2026 |
|
| Fortitude Family Office | 114.00 | $657.996600 | 0% | Mar 2026 |
|
| Royal Bank of Canada | 103.00 | $1.1k | 21% | Mar 2026 |
|
| Parallel Advisors | 49.00 | $282.999500 | 0% | Mar 2026 |
|
| Federated Investors | 34.00 | $195.999800 | 100% | Mar 2026 |
|
| Harbour Investments | 13.00 | $74.999600 | 100% | Mar 2026 |
|
| SBI Securities | 5.00 | $29.000000 | 0% | Mar 2026 |
|
Who sold out of Kalaris Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Redmile Group | Dec 2025 | 83k | $700k |
| Jane Street | Dec 2025 | 33k | $280k |
| OMERS Administration Corporation | Dec 2025 | 30k | $253k |
| Walleye Trading Advisors | Dec 2025 | 11k | $95k |
| Keel Point | Dec 2025 | 10k | $86k |
| Jpmorgan Chase & Co | Sep 2025 | 50.00 | $289.130000 |